Cost Estimate of Immune-Related Adverse Reactions Associated with Innovative Treatments of Metastatic Melanoma

Mennini, Francesco Saverio; Bini, Chiara; Marcellusi, Andrea; Vecchio, Michele Del

doi:10.1007/s40261-018-0690-9

Cited by 14 publications

(5 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the current study, patients treated with ICIs who did not develop irAEs had significantly lower costs and HRU than those developing irAEs that required treatment. Studies previously published examining the costs related to the management of irAEs have been conducted in France [30] and Italy [31], and thus are not comparable to the current study conducted in the U.S. owing to differing health care systems. Compared with chemotherapy, a U.S. real-world study found that ICI monotherapy resulted in fewer AE-related visits among patients with metastatic NSCLC receiving first-line treatment [5].…”

Section: Discussioncontrasting

confidence: 68%

Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors

et al. 2021

View full text Add to dashboard Cite

Background. With increased use of immune checkpoint inhibitors (ICIs) among cancer patients, there is substantial interest in understanding clinical, economics outcomes and management of immune-related adverse events (irAEs). Patients and Methods. A retrospective study was conducted using Premier Healthcare Database, a US national hospital discharge database, from March 1, 2015 through December 31, 2017. The database comprises more than 880 million inpatient and hospital-based outpatient encounters with more than 200 million unique patients reported by 966 hospitals. Patients with four solid tumors known to benefit from ICI therapy were included. The list of irAEs assessed were defined a priori per ASCO clinical guidelines for irAE management. Baseline irAE-related inpatient and outpatient visits were defined as the first inpatient or hospita-based outpatient visit with discharge diagnosis of any irAE of interest following confirmed ICI usage within 90 days prior to the baseline visit. Patients were followed for 90 days post baseline irAE-related inpatient discharge date or outpatient visit date to assess irAE-related inpatient admissions, all-cause inhospital mortality, ICI re-initiation, and to determine costs and healthcare resource utilization.

show abstract

Section: Discussioncontrasting

confidence: 68%

Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Balaji et al reported that around 20% of patients treated with immunotherapy require inpatient hospitalization, with most of these attributed to irAEs. The hospitalization rates for patients receiving dual-agent immunotherapy treatment were notably higher, estimated to have more than a six-fold increase in the odds of hospital admission compared to those treated with single-agent immunotherapy [17,18]. As reported by a single institute study from Massachusetts General Hospital in the United States, the annual cumulative cost of admissions related to irAEs easily reaches into the millions, exceeding USD 3000 per day of admission [19].…”

Section: Discussionmentioning

confidence: 96%

Multisystem Immune-Related Adverse Events from Dual-Agent Immunotherapy Use

Li,

Pond,

McWhirter

2024

Current Oncology

View full text Add to dashboard Cite

Background: little is known about the incidence and characteristics of multisystem immune-related adverse events (irAEs) associated with dual-agent ipilimumab and nivolumab use. Methods: A retrospective cohort review was completed that included cancer patients seen at the Juravinski Cancer Centre who received at least one dose of ipilimumab and nivolumab from 2018 to 2022. Patient characteristics, cancer types, and irAEs were recorded. Multivariate logistic and cox regressions were completed, comparing those who developed multisystem irAEs, single irAE, and no irAE. Results: A total of 123 patients were included in this study. Out of 123 patients, 72 (59%) had melanoma, 50/123 (41%) had renal cell carcinoma (RCC), and 1/123 (1%) had breast cancer. Multisystem irAEs were seen in 40% of the overall cohort. The most common irAE type was dermatitis (22%), followed by colitis (19%) and hepatitis (17%). Conclusions: Our study demonstrated that multisystem irAEs are prevalent amongst patients receiving ipilimumab and nivolumab. It is important for both physician education and the counseling and consent of patients to monitor the potential for multiple irAEs.

show abstract

“…Such predictor could greatly impact clinical practice as it could prompt the early start of add-on therapies, thus possibly preventing the accrual of organ damage. In fact, irAEs are associated with remarkable morbidity and mortality, as well as significant costs [7] that could be reduced with a timely start of second-line therapies.…”

Section: Discussionmentioning

confidence: 99%

Autoantibody positivity predicts severity of rheumatic immune-related adverse events to immune-checkpoint inhibitors

Campochiaro¹,

Farina²,

Tomelleri³

et al. 2022

European Journal of Internal Medicine

View full text Add to dashboard Cite

Cost Estimate of Immune-Related Adverse Reactions Associated with Innovative Treatments of Metastatic Melanoma

Abstract: This study may represent a useful tool to understand the economic burden associated with the management of irAEs associated with patients affected by metastatic melanoma.

Cited by 14 publications

References 27 publications

Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors

Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors

Multisystem Immune-Related Adverse Events from Dual-Agent Immunotherapy Use

Autoantibody positivity predicts severity of rheumatic immune-related adverse events to immune-checkpoint inhibitors

Contact Info

Product

Resources

About